BMEA
Biomea Fusion, Inc.
NASDAQ · Healthcare · Biotechnology · US
$0.85
−2.59%Oct 12, 2026, 20:30 UTC
Biomea Fusion, Inc. announced that it will host a conference call and webcast on October 13, 2026, to announce Phase I results for BMF-650.
Source:Sep 23, 2026, 11:03 UTC
Biomea Fusion terminated its proposed public offering of securities, announced a day earlier, with no securities sold.
Source:Sep 22, 2026, 20:05 UTC
Biomea Fusion, Inc. commenced an underwritten public offering of shares of its common stock and pre-funded warrants to purchase common stock.
Source:Aug 24, 2026, 20:05 UTC
Biomea Fusion Inc completed enrollment for its Phase II diabetes trial, a milestone for its lead metabolic drug program.
Source:Aug 13, 2026, 11:00 UTC
Biomea Fusion dosed the first patient in its OPAL study evaluating icovamenib in combination with semaglutide for obesity, assessing physical function, body weight, body composition, muscle health, and metabolic outcomes.
Source:Jun 5, 2026, 23:32 UTC
Biomea Fusion presented new clinical and translational data for icovamenib at the ADA 86th Scientific Sessions and announced expansion of its Phase I BMF-650 study.